Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss
Huayang Liu(Westlake University), E. Robert McDonald(Novartis (Switzerland)), Gráinne Kerr(Novartis (Switzerland)), Daniel P. Rakiec, Caroline Bullock, Lauren K. Brodeur, Kenzie D. MacIsaac, Joshua M. Korn(Novartis (United States)), Michael D. Jones, Javad Golji(Novartis (United States)), David A. Ruddy(Novartis (Switzerland)), Sosathya Sovath, Joseph D. Growney(Novartis (Switzerland)), Rosalie deBeaumont, Li Li, Franklin Chung, Julie Chen, Michael R. Schlabach(Q Therapeutics (United States)), Raymond Pagliarini(Massachusetts Institute of Technology)
Cited by 369
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Association between Microdeletion and Microduplication at 16p11.2 and Autism
|New England Journal of Medicine|2008|1.7k
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k